Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program

Rhea-AI Summary

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced a business update regarding its nasal spray, Bentrio™, designed to protect against airborne viruses and allergens. This update will be shared during a live conference call and webcast on September 27, 2021, at 8:00 AM ET. Interested participants can join via phone or online, with an archived version available post-event. Altamira is focused on developing therapies addressing unmet medical needs, including RNA therapeutics and treatments for vertigo and tinnitus.

Positive

• Scheduled business update on Bentrio™ indicates ongoing product development.
• Bentrio™ targets protection against airborne viruses and allergens, addressing significant health concerns.

Negative

• None.

HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that it will provide a business update on Bentrio™, its nasal spray for protection against airborne viruses and allergens, through a live conference call and webcast on Monday, September 27, 2021, at 8:00 AM Eastern Time.

To participate telephonically, please dial (888) 506-0062 (U.S.) or (973) 528-0011 (international), conference code 590321. A live, listen-only webcast of the conference call, which will include accompanying slides, can be accessed by visiting the Company's website at www.altamiratherapeutics.com under "Events and Presentations" in the "Investors & Media" section. An archive of the webcast will also be available following the conclusion of the conference call.

About Altamira Therapeutics

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen^® and Sonsuvi^®, Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol "CYTO."

Investor Contact:

Stephen Kilmer
(647) 872-4849
sjk@altamiratherapeutics.com

SOURCE: Altamira Therapeutics Ltd.

View source version on accesswire.com:
https://www.accesswire.com/664843/Altamira-Therapeutics-to-Provide-Business-Update-on-BentrioTM-Program

FAQ

What is the purpose of Altamira Therapeutics' upcoming conference call on September 27, 2021?

The conference call will provide a business update on Bentrio™, a nasal spray for protection against airborne viruses and allergens.

How can I participate in the Altamira Therapeutics conference call?

You can participate by dialing (888) 506-0062 for the U.S. or (973) 528-0011 internationally, using conference code 590321.

What is Bentrio™ from Altamira Therapeutics?

Bentrio™ is a nasal spray developed by Altamira Therapeutics for protection against airborne viruses and allergens.

Where can I find more information about Altamira Therapeutics?

Additional information can be found on Altamira Therapeutics' website under the 'Events and Presentations' section.